| Summary of Significant Segment Expenses |
The Company’s significant segment expenses that are regularly provided to the Company’s CODM are as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
(In thousands) |
|
2026 |
|
|
2025 |
|
REVENUES: |
|
|
|
|
|
|
Total revenue |
|
$ |
392,911 |
|
|
$ |
306,510 |
|
EXPENSES: |
|
|
|
|
|
|
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) |
|
|
61,578 |
|
|
|
49,197 |
|
External R&D expenses: |
|
|
|
|
|
|
Development programs: |
|
|
|
|
|
|
Alixorexton |
|
|
25,497 |
|
|
|
17,854 |
|
LYBALVI |
|
|
4,449 |
|
|
|
3,852 |
|
LUMRYZ |
|
|
2,923 |
|
|
|
— |
|
Other external R&D expenses |
|
|
17,960 |
|
|
|
10,973 |
|
Total external R&D expenses |
|
|
50,829 |
|
|
|
32,679 |
|
Internal R&D expenses: |
|
|
|
|
|
|
Employee-related |
|
|
43,615 |
|
|
|
31,354 |
|
Occupancy |
|
|
3,264 |
|
|
|
3,148 |
|
Depreciation |
|
|
1,688 |
|
|
|
1,467 |
|
Other internal R&D expenses |
|
|
3,949 |
|
|
|
3,169 |
|
Total internal R&D expenses |
|
|
52,516 |
|
|
|
39,138 |
|
R&D expenses |
|
|
103,345 |
|
|
|
71,817 |
|
Selling, general and administrative expenses: |
|
|
|
|
|
|
Selling and marketing expense |
|
|
155,563 |
|
|
|
122,934 |
|
General and administrative expense |
|
|
109,030 |
|
|
|
48,770 |
|
Total selling, general and administrative expense |
|
|
264,593 |
|
|
|
171,704 |
|
Other segment (expense) income (1) |
|
|
(29,875 |
) |
|
|
8,672 |
|
NET INCOME |
|
|
(66,480 |
) |
|
|
22,464 |
|
(1)“Other segment (expense) income” during the three months ended March 31, 2026 and 2025, includes “Amortization of acquired intangible assets”, “Other (expense) income, net” and “Income tax provision”.
|